CLINICAL TRIALS PROFILE FOR RANITIDINE HYDROCHLORIDE

505(b)(2) Clinical Trials for ranitidine hydrochloride

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
OTC	NCT00443963 ↗	Total Antioxidant Effects of Esomeprazole in Dyspeptic Patients Receiving Non-steroidal Anti-inflammatory Drugs	Withdrawn	AstraZeneca	Phase 4	2006-12-01	The principal investigator hypothesizes that participants receiving NSAID drugs with dyspeptic symptoms have increased production of gastric levels of free radicals. The primary objective of the study is to determine if Esomeprazole Magnesium increases gastric total antioxidant capacity and decreases gastric free radical production in humans. Participants (age 18 years and older) with no history of upper GI bleeding who are receiving non-steroidal anti-inflammatory drugs and then develop dyspepsia will be recruited from our primary care clinic in Washington, DC. All eligible participants will undergo biopsies of antrum and corpus. The participants will be randomized to receive either Zantac OTC or Nexium for 15 days. On day 15, all participants will undergo repeat upper endoscopy to obtain biopsies of antrum and corpus. Tissue samples will then be extracted to determine total antioxidant capacity and lipid peroxide levels (as an indirect marker of free radical production).
OTC	NCT00443963 ↗	Total Antioxidant Effects of Esomeprazole in Dyspeptic Patients Receiving Non-steroidal Anti-inflammatory Drugs	Withdrawn	Medstar Health Research Institute	Phase 4	2006-12-01	The principal investigator hypothesizes that participants receiving NSAID drugs with dyspeptic symptoms have increased production of gastric levels of free radicals. The primary objective of the study is to determine if Esomeprazole Magnesium increases gastric total antioxidant capacity and decreases gastric free radical production in humans. Participants (age 18 years and older) with no history of upper GI bleeding who are receiving non-steroidal anti-inflammatory drugs and then develop dyspepsia will be recruited from our primary care clinic in Washington, DC. All eligible participants will undergo biopsies of antrum and corpus. The participants will be randomized to receive either Zantac OTC or Nexium for 15 days. On day 15, all participants will undergo repeat upper endoscopy to obtain biopsies of antrum and corpus. Tissue samples will then be extracted to determine total antioxidant capacity and lipid peroxide levels (as an indirect marker of free radical production).
OTC	NCT03145012 ↗	Histamine Receptor 2 Antagonists as Enhancers of Anti-Tumour Immunity	Unknown status	Dalhousie University	Phase 4	2018-05-01	The immune response against tumors can be highly effective in preventing tumor development, growth and metastasis under certain circumstances. However, tumor associated immune suppression can profoundly limit the impact of natural tumor immunity and also reduce the effectiveness of tumor immunotherapy strategies. A major component of tumor associated immune suppression is mediated by myeloid cells, especially the monocytic subset of myeloid derived suppressor cells (MDSC). In recent studies that were conducted through a CCSRI Innovation grant, the investigators discovered that oral treatment of mice with the commonly used histamine receptor 2 (H2) antagonists ranitidine or famotidine inhibits both primary breast tumor development and metastasis, in three distinct mouse tumor models and reduces the numbers of monocytic MDSC. These findings have enormous potential to aid in effective cancer immunotherapy and may have immediate implications for cancer patients. The objective of this investigation is to determine whether treatment with the H2 receptor antagonist ranitidine alters immune suppression, through modulation of immune cell populations. The investigators will examine peripheral blood monocyte, neutrophil and NK cell numbers, subsets and activation status from healthy volunteers treated for 6 weeks with daily oral ranitidine. Ranitidine is widely available and used over the counter in Canada. These drugs are widely recognized as safe, well tolerated and have very few side effects. It has been suggested that among the general population, over 10% of those over the age of 65 take such medications on a regular basis for relief against gastrointestinal discomfort. The outcome of pre-clinical studies in mice warrant further investigation into transferability to humans. If the outcome of the current proposal proves to be viable, then these drugs could provide a safe method to reduce tumor associated immunosuppression with broad implications, both for current cancer patients and for those at high risk of developing cancer. Further to this, the outcome of our proposal may provide a new strategy for improving the effectiveness of T-cell mediated immunotherapy.
OTC	NCT03145012 ↗	Histamine Receptor 2 Antagonists as Enhancers of Anti-Tumour Immunity	Unknown status	Nova Scotia Health Authority	Phase 4	2018-05-01	The immune response against tumors can be highly effective in preventing tumor development, growth and metastasis under certain circumstances. However, tumor associated immune suppression can profoundly limit the impact of natural tumor immunity and also reduce the effectiveness of tumor immunotherapy strategies. A major component of tumor associated immune suppression is mediated by myeloid cells, especially the monocytic subset of myeloid derived suppressor cells (MDSC). In recent studies that were conducted through a CCSRI Innovation grant, the investigators discovered that oral treatment of mice with the commonly used histamine receptor 2 (H2) antagonists ranitidine or famotidine inhibits both primary breast tumor development and metastasis, in three distinct mouse tumor models and reduces the numbers of monocytic MDSC. These findings have enormous potential to aid in effective cancer immunotherapy and may have immediate implications for cancer patients. The objective of this investigation is to determine whether treatment with the H2 receptor antagonist ranitidine alters immune suppression, through modulation of immune cell populations. The investigators will examine peripheral blood monocyte, neutrophil and NK cell numbers, subsets and activation status from healthy volunteers treated for 6 weeks with daily oral ranitidine. Ranitidine is widely available and used over the counter in Canada. These drugs are widely recognized as safe, well tolerated and have very few side effects. It has been suggested that among the general population, over 10% of those over the age of 65 take such medications on a regular basis for relief against gastrointestinal discomfort. The outcome of pre-clinical studies in mice warrant further investigation into transferability to humans. If the outcome of the current proposal proves to be viable, then these drugs could provide a safe method to reduce tumor associated immunosuppression with broad implications, both for current cancer patients and for those at high risk of developing cancer. Further to this, the outcome of our proposal may provide a new strategy for improving the effectiveness of T-cell mediated immunotherapy.

All Clinical Trials for ranitidine hydrochloride

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000964 ↗	The Effect of Stomach Acid on Foscarnet	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1	1969-12-31	To see if ranitidine, by reducing stomach acidity, can enhance the effectiveness of foscarnet, by making foscarnet more available to the body. Foscarnet is an antiviral compound. Laboratory studies have shown it to be active against HIV. However, only 12 - 22 percent of an oral foscarnet dose is absorbed by the body. Ranitidine suppresses gastric acid output, increasing gastric pH. Thus by increasing gastric pH (decreasing stomach acidity), less foscarnet is expected to be decomposed or broken down in the stomach. Thus, more foscarnet should be absorbed into the body.
NCT00002106 ↗	A Pilot Randomized, Double-Blind, Placebo-Controlled, Parallel Design, Multicenter Trial to Evaluate the Effect of Ranitidine on Immunologic Indicators in Asymptomatic HIV-1 Infected Subjects With a CD4 Cell Count Between 400-700 Cells/mm3	Completed	Glaxo Wellcome	Phase 2	1969-12-31	To evaluate the effect of ranitidine on immunologic indicators in asymptomatic HIV-1 infected patients with CD4 counts of 400-700 cells/mm3.
NCT00030992 ↗	BMS 247550 to Treat Kidney Cancer	Completed	National Cancer Institute (NCI)	Phase 2	2002-02-01	This study will examine whether the experimental drug BMS 247550 (Ixabepilone) is an effective treatment for kidney cancer. BMS 247550 belongs to a class of drugs called epothilones that interfere with the ability of cancer cells to divide. In the way they kill cells, they are very similar to a class of compounds known as the taxanes, which include the drug Taxol. Other characteristics of the epothilones, however, enable them to work in cells that are resistant to Taxol. Patients 18 years of age or older with kidney cancer that has not spread to the central nervous system (unless the brain tumor has remained stable for at least six months after surgical or radiation treatment) may be eligible for this study. Pregnant or nursing women may not participate. Candidates are screened with various tests that may include blood and urine tests, electrocardiogram (EKG), and chest x-ray. Computerized tomography (CT) scans or X-rays, and possibly nuclear medicine studies may be done to determine the extent of disease. Participants receive BMS 247550 by a 1-hour infusion into a vein for 5 consecutive days (days 1, 2, 3, 4 and 5) of each 21-day treatment cycle. Patients must stay in the National Institutes of Health (NIH) area near Bethesda, Maryland, for 7 to 8 days during the first treatment cycle and for the 5 days of treatment in subsequent cycles. The total number of cycles will vary among patients, depending on their individual clinical situation. The drug dose may be increased gradually in subsequent cycles in patients who can tolerate such increases. In addition, participants undergo the following tests and procedures: - Periodic physical examinations and frequent blood tests - X-ray and other imaging studies to determine if the tumor is responding to the treatment. - Tumor biopsies to confirm the diagnosis or spread of tumor and to examine the reaction of certain proteins in cancer cells to BMS 247550. Two biopsies will be done. For this procedure, a small piece of tumor tissue is withdrawn through a needle under local anesthetic. Treatment will be stopped in patients whose tumor grows while receiving BMS 247550. Patients whose tumor disappears completely will be followed at NIH periodically for examinations and tests. Patients whose disease does not completely resolve or whose disease recurs may be advised of other appropriate research protocols at NIH or, if none are available, will be returned to the care of their local doctor.
NCT00037570 ↗	Study Evaluating Pantoprazole in Peptic Ulcer Hemorrhage	Completed	Wyeth is now a wholly owned subsidiary of Pfizer	Phase 2	2000-11-01	This is a multicenter, randomized, double-blind, parallel-group, dose-ranging, comparator-controlled study of the effect of pantoprazole on intragastric pH after successful endoscopic hemostasis in hospitalized patients. Patients will receive either intravenous pantoprazole (one of two regimens) or ranitidine (the comparator) within 2 hours of successful hemostasis and administration will continue for 72 hours after hemostasis.

Clinical Trial Conditions for ranitidine hydrochloride

Condition Name

Condition Name for ranitidine hydrochloride
Intervention	Trials
Healthy	7
Postoperative Pain	6
Dyspepsia	4
Breast Cancer	3

Condition MeSH

Condition MeSH for ranitidine hydrochloride
Intervention	Trials
Hypotension	9
Ulcer	8
Pain, Postoperative	8
Gastroesophageal Reflux	7

Clinical Trial Locations for ranitidine hydrochloride

Trials by Country

Trials by Country for ranitidine hydrochloride
Location	Trials
United States	87
Egypt	25
China	20
Korea, Republic of	12
Italy	8

Trials by US State

Trials by US State for ranitidine hydrochloride
Location	Trials
California	13
Texas	10
Florida	6
Illinois	4
Pennsylvania	4

Clinical Trial Progress for ranitidine hydrochloride

Clinical Trial Phase

Clinical Trial Phase for ranitidine hydrochloride
Clinical Trial Phase	Trials
PHASE4	1
PHASE1	1
Phase 4	39

Clinical Trial Status

Clinical Trial Status for ranitidine hydrochloride
Clinical Trial Phase	Trials
Completed	89
Unknown status	18
Terminated	10

Clinical Trial Sponsors for ranitidine hydrochloride

Sponsor Name

Sponsor Name for ranitidine hydrochloride
Sponsor	Trials
AstraZeneca	6
Cairo University	5
Kasr El Aini Hospital	5

Sponsor Type

Sponsor Type for ranitidine hydrochloride
Sponsor	Trials
Other	134
Industry	47
NIH	6

Ranitidine Hydrochloride Clinical Trials Update, Market Analysis, and Downstream Commercial Projection (U.S. and Key Markets)

Last updated: July 26, 2026

Executive summary

Ranitidine hydrochloride’s global commercialization is structurally impaired because major regulators (including FDA in the U.S.) eliminated marketing authorization for ranitidine products tied to NDMA contamination risk. This regulatory outcome suppresses new patient demand, halts routine commercial sales in most developed markets, and makes “clinical trials update” activity largely confined to: (1) discontinued program readouts, (2) risk-based reformulation attempts by select parties, and (3) limited, non-routine clinical or analytical studies focused on NDMA control rather than new therapeutic expansion. For any near-term market projection, the base case is continued volume contraction, with remaining revenue dominated by legacy inventory run-out where permitted and by jurisdictions that maintain local authorization.

What happened to ranitidine hydrochloride and why did regulators pull it?

Direct answer: Ranitidine’s commercialization was discontinued after regulators determined unacceptable NDMA contamination risk. In the U.S., FDA requested removal of all ranitidine products from the market (and barred new distribution) after NDMA was detected at potentially harmful levels.

FDA actions that drive market collapse

• FDA requested withdrawal/discontinuation of ranitidine products in the U.S. after NDMA findings (FDA communications, 2019 and follow-on updates).
• The regulatory posture ended routine retail distribution and undermined any expectation of mainstream new prescribing.

EU and other major regulators

• EU-level actions and member-state measures followed similar NDMA contamination concerns; the practical effect was near-universal product removal or suspension in Europe’s major consumer channels.
• Market impact is therefore not just demand destruction but also channel shutdown and supply interruption.

What clinical trials are still active for ranitidine hydrochloride?

Direct answer: Public clinical trial activity is limited and does not track a standard “late-stage pipeline” profile. The dominant trial themes are not new indications with registrational endpoints. Instead, clinical activity (when present) is typically restricted to: NDMA control assessments, formulation/analytics studies, or non-registrational investigations.

What “trial updates” usually look like post-withdrawal

• No meaningful phase 3 new-indication expansion in the mainstream ranitidine program.
• Analytical and stability studies that evaluate NDMA formation under storage/handling conditions.
• Alternative synthesis or impurity-control approaches aimed at reducing NDMA generation, often preclinical or chemistry-focused rather than proof-of-efficacy trials.

Are there any new reformulation or NDMA-control programs for ranitidine hydrochloride?

Direct answer: If reformulation programs exist, they are aimed at impurity control rather than therapeutic innovation. The core barrier is that even if new formulations reduce NDMA formation, the regulatory pathway still requires credible impurity limits, stability evidence, and compliance demonstrations.

Key technical pressure points regulators weigh

• NDMA formation during shelf-life and under stress conditions.
• Lot-to-lot variability of NDMA and related nitrosamines.
• Analytical method validation for detecting trace nitrosamines.

What is the current market size and revenue mix for ranitidine hydrochloride?

Direct answer: Market size has sharply contracted from historical levels. Remaining demand is largely constrained to residual stock run-off, limited country authorizations, and niche availability where regulators did not impose a full stop.

Revenue drivers now

• Regulatory availability (authorization status per country)
• Switching to alternatives: PPIs and other H2 blockers (e.g., famotidine where authorized)
• Inventory depletion where product remains in distribution

What changed versus “pre-2019” economics

• Pricing power disappeared because supply is constrained and distribution is curtailed.
• Brand switching and therapeutic class substitution accelerate demand loss.

Which therapeutics substitute for ranitidine hydrochloride and how does that affect demand?

Direct answer: Patients and prescribers substituted toward acid-suppressing alternatives, which reduces ranitidine’s addressable market regardless of local inventory.

Substitution pattern likely affects every projection

• Proton pump inhibitors: primary substitution for GERD and ulcer indications.
• Other H2 blockers: second-line substitution for specific histamine-mediated indications.
• Class substitution reduces ceiling for any “return” scenario unless regulators fully reopen authorization.

How long will ranitidine hydrochloride remain commercial (forecast horizon)?

Direct answer: With the U.S. and major developed markets effectively shut, the remaining commercial life is mostly a function of remaining inventory and local regulatory discretion, not a new clinical development clock.

Base case forecast (directional, commercial)

• Continued decline as inventories clear.
• Low likelihood of meaningful re-entry in the U.S. absent a regulator-driven pathway to reinstatement that overcomes NDMA risk with strong evidence.

Market projection scenarios: what happens by year?

Direct answer: Three scenario bands are relevant: “continued shutdown,” “partial reinstatement in select markets,” and “full reinstatement in major markets.” The base case is continued shutdown.

Scenario table (directional projections)

Timeframe	Continued shutdown (base case)	Partial reinstatement in select markets	Full reinstatement (low probability)
12 months	further inventory depletion, minimal new demand	limited restart where authorization returns	limited, if any, U.S. scale-up
2-3 years	near-zero recurring volume in most developed markets	modest regional stabilization	higher but still competitive pressure from PPIs
3-5 years	persistent low-tear demand	small regional market	normalization only if NDMA risk fully controlled

What is the competitive landscape for ranitidine replacement?

Direct answer: The competitive set is dominated by class substitutes and availability of authorized acid suppressants, not by other ranitidine brands.

Competitive dynamics

• PPIs capture most GERD/ulcer patients.
• H2 blocker competition depends on nitrosamine compliance status and local authorization.
• OTC channel availability matters as much as prescription share after regulatory withdrawals.

What patents protect ranitidine hydrochloride and how do they affect the market?

Direct answer: The active ingredient is old and generics historically dominated. Patent leverage is unlikely to be the central driver of commercialization today. Regulatory status is the primary driver.

Patent estate reality for older small molecules

• Many ranitidine patents likely expired long ago, meaning generic manufacturing is not protected by active legal barriers.
• Even if manufacturing is legally feasible, regulatory authorization for product distribution is the binding constraint.

What are the key regulatory risks for any attempt to restart ranitidine?

Direct answer: The NDMA/nitrosamine risk is the gating factor. Any restart attempt must satisfy:

• impurity limits and NDMA control,
• stability indicating methods,
• regulatory review and potential re-labeling.

Regulatory “stop” variables

• Failure to demonstrate acceptable NDMA formation across time and storage conditions.
• Analytical method shortcomings that regulators reject.
• Batch variability that breaches impurity specifications.

How does regulatory status translate into clinical development feasibility?

Direct answer: When marketing authorization is suspended or withdrawn, trials aimed at expanding use face practical barriers: recruitment, sponsor incentive, and clinical endpoint relevance. Without a credible regulatory pathway for re-authorization, late-stage trials become commercially unattractive.

Key takeaways

• Ranitidine hydrochloride’s clinical and commercial trajectory is dominated by NDMA contamination regulatory action, not by new evidence of therapeutic value.
• “Clinical trials updates” are limited and skew toward impurity/analytical or discontinuation-related studies rather than registrational programs.
• Market projection is driven by product availability and substitution to PPIs and other H2 blockers.
• The base case is continued market contraction, with any recovery requiring a regulator-approved product-level NDMA risk solution and reinstatement of authorization.

FAQs

1) Is ranitidine hydrochloride still sold in the U.S.?

No. U.S. availability is effectively ended following FDA action requesting market withdrawal tied to NDMA contamination risk.

2) Are there any ongoing Phase 3 trials for new ranitidine indications?

Publicly, there is no dominant signal of Phase 3 registrational activity typical of a late-stage pipeline; most activity is limited and non-registrational in nature post-withdrawal.

3) What substitutes for ranitidine are most commonly used?

Proton pump inhibitors are the primary substitutes for GERD and ulcer indications, with other H2 blockers used depending on patient and prescriber context.

4) What would be required to restart ranitidine sales in a major market?

A regulator-supported pathway that demonstrates controlled NDMA formation, validated analytical methods, acceptable stability data, and compliance across lots.

5) Does patent expiry matter for ranitidine’s market outlook?

Patent expiry is not the key driver. Regulatory authorization and impurity risk control determine whether products can be marketed at scale.

References

1. U.S. Food and Drug Administration (FDA). Drug Safety Communications on ranitidine and NDMA (2019 and related updates).
2. European Medicines Agency (EMA). Scientific guidance and public communications relating to nitrosamine impurities and ranitidine-containing products (2019 onward).